Pretreatment Assessment of Tumor Enhancement on Contrast-Enhanced Computed Tomography as a Potential Predictor of Treatment Outcome in Metastatic Renal Cell Carcinoma Patients Receiving Antiangiogenic Therapy

被引：53

作者：

Han, Kyung Seok ^{[1
,2
,3
]}

Jung, Dae Chul ^{[4
]}

Choi, Hyuck Jae ^{[5
]}

Jeong, Min Soo ^{[6
]}

Cho, Kang Su ^{[3
]}

Joung, Jae Young ^{[3
]}

Seo, Ho Kyung ^{[3
]}

Lee, Kang Hyun ^{[3
]}

Chung, Jinsoo ^{[3
]}

机构：

[1] Yonsei Univ, Coll Med, Dept Urol, Seoul, South Korea

[2] Yonsei Univ, Coll Med, Urol Sci Inst, Seoul, South Korea

[3] Natl Canc Ctr, Ctr Specif Organs Canc, Urol Oncol Clin, Goyang, South Korea

[4] Natl Canc Ctr, Dept Radiol, Goyang, South Korea

[5] Asan Med Ctr, Dept Radiol, Seoul, South Korea

[6] Seoul Natl Univ Hosp, Dept Urol, Seoul 110744, South Korea

来源：

CANCER | 2010年 / 116卷 / 10期

关键词：

renal cell carcinoma; metastasis; targeted therapy; computed tomography; attenuation; contrast enhancement; response; prognosis; INTERFERON-ALPHA; PTK787/ZK-222584; SURVIVAL; CANCER; SORAFENIB; INHIBITOR; SUNITINIB; BIOMARKER; CT;

D O I：

10.1002/cncr.25019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Tumor vascularity is a potential predictor of treatment outcomes in metastatic renal cell carcinoma (mRCC), and contrast enhancement of tumors in computed tomography (CT) is correlated significantly with micro-vessel density In this study, the authors investigated whether tumor enhancement in contrast-enhanced CT (CECT) is useful for predicting outcomes in patients with mRCC who are receiving antiangiogenic therapy METHODS: Attenuation values were reviewed retrospectively on CECT images of all metastatic lesions in 66 patients from February 2007 to November 2008 All patients received a tyrosine kinase inhibitor (either sunitinib or sorafenib) Tumor response was evaluated on CECT studies every 12 weeks The authors analyzed the association between contrast enhancement and treatment outcomes, including objective response, tumor size reduction rate, time to response, and time to progression RESULTS: in 46 patients, 198 metastatic lesions were assessed Tumor size was reduced in 140 lesions (70 7%) and was increased in 58 lesions (29 3%) The mean reduction in size was 23 8% The overall mean time to response and the time to progression were 8 6 months and 16 4 months, respectively In multivariate analyses, tumor enhancement and enhancement pattern were associated with objective responses (P = 003 and P = 028, respectively) In addition, tumor enhancement was associated with tumor size reduction (P = 004) In Cox proportional hazards models, only tumor enhancement was associated significantly with the time to size reduction and progression-free survival (P = 03 and P = 015, respectively) CONCLUSIONS: Tumor enhancement on CECT images was associated with treatment outcomes and was identified as a potential predictor of treatment outcomes after antiangiogenic therapy in patients with mRCC Cancer 2010;116:2332-42. (C) 2010 American Cancer Society

引用

页码：2332 / 2342

页数：11

共 31 条

[1]

Anderson SA, 2000, MAGNET RESON MED, V44, P433, DOI 10.1002/1522-2594(200009)44:3<433::AID-MRM14>3.0.CO

[2]

2-9

[3]

Anti-angiogenic therapy in the treatment of advanced renal cell cancer [J].

Board, Ruth E. ;

Thistlethwaite, Fiona C. ;

Hawkins, Robert E. .

CANCER TREATMENT REVIEWS, 2007, 33 (01) :1-8

[4]

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy [J].

Choueiri, Toni K. ;

Garcia, Jorge A. ;

Elson, Paul ;

Khasawneh, Mohamad ;

Usman, Saif ;

Golshayan, Ali Reza ;

Baz, Rachid C. ;

Wood, Laura ;

Rini, Brian I. ;

Bukowski, Ronald M. .

CANCER, 2007, 110 (03) :543-550

[5]

Rising incidence of renal cell cancer in the United States [J].

Chow, WH ;

Devesa, SS ;

Warren, JL ;

Fraumeni, JF .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1628-1631

[6]

Magnetic resonance imaging - Measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma [J].

de Bazelaire, Cedric ;

Alsop, David C. ;

George, Daniel ;

Pedrosa, Ivan ;

Wang, Yongyu ;

Michaelson, M. Dror ;

Rofsky, Neil M. .

CLINICAL CANCER RESEARCH, 2008, 14 (17) :5548-5554

[7]

Drevs J, 2002, CANCER RES, V62, P4015

[8]

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[9]

Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[10]

Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) [J].

Figlin, R. A. ;

Hutson, T. E. ;

Tomczak, P. ;

Michaelson, M. D. ;

Bukowski, R. M. ;

Negrier, S. ;

Huang, X. ;

Kim, S. T. ;

Chen, I. ;

Motzer, R. J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 →